Equities analysts forecast that Karyopharm Therapeutics Inc (NASDAQ:KPTI) will post $1.15 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Karyopharm Therapeutics’ earnings, with estimates ranging from $50,000.00 to $2.46 million. Karyopharm Therapeutics posted sales of $1.53 million in the same quarter last year, which would indicate a negative year over year growth rate of 24.8%. The business is scheduled to issue its next earnings results on Thursday, March 21st.
According to Zacks, analysts expect that Karyopharm Therapeutics will report full-year sales of $30.61 million for the current year, with estimates ranging from $30.10 million to $32.59 million. For the next year, analysts forecast that the company will report sales of $21.67 million, with estimates ranging from $4.72 million to $45.98 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Karyopharm Therapeutics.
Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Thursday, November 8th. The company reported ($0.79) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.88) by $0.09. Karyopharm Therapeutics had a negative return on equity of 104.50% and a negative net margin of 502.90%. The business had revenue of $0.24 million during the quarter, compared to analyst estimates of $1.21 million.
A number of research firms recently weighed in on KPTI. Zacks Investment Research upgraded Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research report on Thursday. BidaskClub upgraded Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, January 7th. Bank of America upgraded Karyopharm Therapeutics from an “underperform” rating to a “neutral” rating in a research report on Thursday, January 3rd. HC Wainwright reiterated a “buy” rating on shares of Karyopharm Therapeutics in a research report on Monday, December 3rd. Finally, B. Riley began coverage on Karyopharm Therapeutics in a research report on Friday, November 30th. They issued a “buy” rating and a $23.00 price target for the company. Three investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $21.90.
In other Karyopharm Therapeutics news, insider Sharon Shacham sold 10,000 shares of the firm’s stock in a transaction dated Thursday, October 18th. The stock was sold at an average price of $12.63, for a total transaction of $126,300.00. Following the completion of the sale, the insider now directly owns 713,510 shares in the company, valued at approximately $9,011,631.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael Kauffman sold 9,600 shares of the firm’s stock in a transaction dated Monday, November 26th. The stock was sold at an average price of $11.00, for a total value of $105,600.00. Following the sale, the chief executive officer now owns 521,743 shares of the company’s stock, valued at $5,739,173. The disclosure for this sale can be found here. Insiders have sold a total of 57,500 shares of company stock valued at $636,231 over the last 90 days. Corporate insiders own 13.26% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC acquired a new stake in shares of Karyopharm Therapeutics during the 3rd quarter valued at about $195,000. Verition Fund Management LLC acquired a new stake in shares of Karyopharm Therapeutics during the 3rd quarter valued at about $242,000. Fox Run Management L.L.C. acquired a new stake in shares of Karyopharm Therapeutics during the 3rd quarter valued at about $266,000. Metropolitan Life Insurance Co. NY raised its stake in shares of Karyopharm Therapeutics by 38.9% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 16,275 shares of the company’s stock valued at $277,000 after acquiring an additional 4,556 shares in the last quarter. Finally, Voya Investment Management LLC raised its stake in shares of Karyopharm Therapeutics by 24.3% in the 2nd quarter. Voya Investment Management LLC now owns 18,661 shares of the company’s stock valued at $317,000 after acquiring an additional 3,653 shares in the last quarter. Hedge funds and other institutional investors own 71.21% of the company’s stock.
Shares of NASDAQ:KPTI traded down $0.08 during midday trading on Wednesday, reaching $10.09. The company had a trading volume of 285,517 shares, compared to its average volume of 529,138. Karyopharm Therapeutics has a 1-year low of $8.01 and a 1-year high of $21.71. The firm has a market capitalization of $621.04 million, a price-to-earnings ratio of -3.59 and a beta of 3.36.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.
Featured Story: What are the components of an earnings report?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.